BAJAJ BROKING
Zydus Lifesciences received USFDA approval to produce generic Enzalutamide tablets for prostate cancer. The drug generated $1.4 billion in US sales annually and will be manufactured in Ahmedabad.
Zydus Lifesciences, one of India’s leading pharmaceutical companies, has secured tentative approval from the US Food and Drug Administration (USFDA) to manufacture generic Enzalutamide tablets. These tablets, in doses of 40 mg and 80 mg, are used to treat patients suffering from castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
The company has announced that the production of Enzalutamide tablets will take place at its state-of-the-art manufacturing facility located in the Special Economic Zone (SEZ) in Ahmedabad. This approval marks an important milestone for Zydus Lifesciences as it further strengthens its foothold in the global pharmaceutical market, particularly in oncology treatments.
Enzalutamide is an androgen receptor inhibitor, which is a crucial treatment for advanced stages of prostate cancer. According to IQVIA data from July 2024, the US market for Enzalutamide tablets (40 mg and 80 mg) is significant, with annual sales of $1,417.2 million. The US FDA's approval provides Zydus with an opportunity to tap into this lucrative market with its generic version, creating potential competition in a field currently dominated by branded drugs.
Zydus Lifesciences has steadily built an impressive portfolio of generic drugs, with the company now securing 400 approvals from the US FDA. Since it began filing Abbreviated New Drug Applications (ANDAs) in FY 2003-04, Zydus has submitted over 465 ANDAs, positioning itself as a major player in the generic drug industry.
Prostate cancer is one of the most common cancers affecting men worldwide, with increasing demand for effective treatments. Introducing a more affordable generic version of Enzalutamide in the US market is expected to benefit patients by improving access to life-saving medication. Zydus Lifesciences’ foray into the prostate cancer treatment market with the approval of this drug aligns with global healthcare efforts to meet the rising demand for cancer treatments.
Zydus Lifesciences’ latest US FDA approval signifies the company’s growing expertise in oncology treatments. With the launch of its generic Enzalutamide tablets, the firm is poised to expand its market reach further.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading